We initially tested the IdyllaTMBRAF Mutation Test (hereafter referred to as Idylla) capacity to detect BRAF V600 mutations using 73 unprocessed (i.e., without macro- or micro dissection) FFPE tumor samples from patients with diverse cancers (melanoma, n = 30; colorectal cancer, n = 23; non-small cell lung cancer [NSCLC], n = 12; papillary thyroid cancer, n = 5; breast cancer, n = 3) obtained from commercial suppliers as outlined in Methods section (Table 2). Here, BRAF is linked to thyroid gland papillary carcinoma.